sur Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Updates Progress on High-Dose Sublingual Aspirin
Aspire Biopharma Holdings, Inc. announced the completion of initial feasibility studies for its high-dose sublingual aspirin. This soluble, fast-acting formulation aims to enhance cardiology emergency and pain management through rapid absorption. Aspire expects to commence Phase 1 clinical trials in April.
The FDA testing, conducted by Glatt Air Techniques, validated the product's compliance with cGMP standards. Testing confirmed ingredient compatibility, establishing a clear path for further development. Aspire remains focused on leveraging the aspirin's established safety profile to expedite approval processes.
Looking ahead, Aspire anticipates several key milestones in 2025, including FDA meetings, clinical trials, and potential product launches in various segments such as testosterone formulations and non-prescription wellness supplements.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Aspire Biopharma, Inc.